Lancet Rheumatology最新文献

{"title":"Laura Coates: all about the people","authors":"Heather Van Epps","doi":"10.1016/S2665-9913(25)00107-9","DOIUrl":"10.1016/S2665-9913(25)00107-9","url":null,"abstract":"","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":"7 5","pages":"Page e313"},"PeriodicalIF":15.0,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143873444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumour necrosis factor inhibitor safety in rheumatoid arthritis with early-stage cancer","authors":"Jeffrey A Sparks , Namrata Singh","doi":"10.1016/S2665-9913(25)00099-2","DOIUrl":"10.1016/S2665-9913(25)00099-2","url":null,"abstract":"","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":"7 5","pages":"Pages e307-e308"},"PeriodicalIF":15.0,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143873439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research in Brief","authors":"Jennifer Thorley","doi":"10.1016/S2665-9913(25)00106-7","DOIUrl":"10.1016/S2665-9913(25)00106-7","url":null,"abstract":"","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":"7 5","pages":"Page e312"},"PeriodicalIF":15.0,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143873443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting the most vulnerable—a step too far","authors":"The Lancet Rheumatology","doi":"10.1016/S2665-9913(25)00103-1","DOIUrl":"10.1016/S2665-9913(25)00103-1","url":null,"abstract":"","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":"7 5","pages":"Page e303"},"PeriodicalIF":15.0,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143873609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pneumatosis cystoides intestinalis in overlap syndrome.","authors":"May Shuen Tang, Gim Gee Teng","doi":"10.1016/S2665-9913(25)00075-X","DOIUrl":"https://doi.org/10.1016/S2665-9913(25)00075-X","url":null,"abstract":"","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":" ","pages":""},"PeriodicalIF":15.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143789120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gout: the deeply rooted image of the self-inflicted disease of kings comes from misinterpreting history.","authors":"Tristan Pascart, Emmanuel Drouin","doi":"10.1016/S2665-9913(25)00069-4","DOIUrl":"https://doi.org/10.1016/S2665-9913(25)00069-4","url":null,"abstract":"","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":" ","pages":""},"PeriodicalIF":15.0,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143781452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is type I interferon score a promising circulating biomarker for systemic sclerosis?","authors":"Yuichiro Shirai, Masataka Kuwana","doi":"10.1016/S2665-9913(25)00030-X","DOIUrl":"https://doi.org/10.1016/S2665-9913(25)00030-X","url":null,"abstract":"","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":" ","pages":""},"PeriodicalIF":15.0,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143781463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum type I interferon score as a disease activity biomarker in patients with diffuse cutaneous systemic sclerosis: a retrospective cohort study.","authors":"Monique Hinchcliff, Dinesh Khanna, Enrico De Lorenzis, Stefano Di Donato, Antonio Carriero, Rebecca L Ross, Suiyuan Huang, Kathleen A Aren, Elana J Bernstein, Mary Carns, Flavia V Castelino, Robyn T Domsic, Tracy M Frech, Jessica K Gordon, Faye N Hant, Ami A Shah, Victoria K Shanmugam, Virginia D Steen, Shervin Assassi, Francesco Del Galdo","doi":"10.1016/S2665-9913(24)00403-X","DOIUrl":"https://doi.org/10.1016/S2665-9913(24)00403-X","url":null,"abstract":"<p><strong>Background: </strong>Type I interferon (IFN) pathway activation has been associated with severe systemic sclerosis. We aimed to examine the association of serum IFN scores with disease activity and outcomes in two cohorts of patients with diffuse cutaneous systemic sclerosis.</p><p><strong>Methods: </strong>In this retrospective cohort study, we included adult (aged >18 years) patients with diffuse cutaneous systemic sclerosis enrolled in the US Prospective Registry of Early Systemic Sclerosis (PRESS; incident cohort) or in the UK observational cohort (Stratification for Risk of Progression in Scleroderma [STRIKE]; prevalent cohort) registries and healthy controls (volunteers). Sera were analysed by Myriad-Rules Based Medicine's Luminex xMAP Technology Multiplex Assay (Austin, TX, USA), and IFN scores were generated using concentrations of CCL2, CCL8, CCL19, CXCL9, CXCL10, and CXCL11. Patients were classified as IFN-high (vs IFN-low) when mean sum of the natural logarithm of the six chemokines was greater than (or within) two standard deviations of healthy controls. The main outcome measures were the baseline and the minimal clinically important differences for modified Rodnan Skin Score, forced vital capacity (FVC), diffusing capacity for carbon monoxide (DLCO), and Health Assessment Questionnaire-Disability Index at 12 months. A person with lived experience of systemic sclerosis was involved in writing the report.</p><p><strong>Findings: </strong>Patients with diffuse cutaneous systemic sclerosis in the PRESS incident cohort were recruited between April 1, 2012, and Jan 1, 2019, and healthy controls and patients in the STRIKE prevalent cohort were recruited between Dec 1, 2014, and Dec 1, 2018. IFN scores were generated for 110 patients in the incident cohort (mean age 50·2 years [SD 15·0], 76 [69%] women and 34 [31%] men, 87 [79%] White) and 72 patients in the prevalent cohort (mean age 51·7 years [SD 10·9], 50 [69%] women and 22 [31%] men, 64 [89%] White), and 32 healthy controls (mean age 47·0 years [SD 12·4]; 19 [59%] women and 13 [41%] men; 24 [75%] White). 50 (45%) of 110 patients in the incident cohort and 27 (38%) of 72 patients in the prevalent cohort were classified as IFN-high. In the incident cohort, patients classified as IFN-high had worse baseline disease compared with patients classified as IFN-low, as assessed by mean predicted FVC (72·0% [SD 18·9] vs 85·3% [18·5]; p=0·0028), DLCO (56·8% [SD 21·6] vs 76·6% [25·3]; p=0·0008), and median Health Assessment Questionnaire-Disability Index (1·4 [IQR 0·8-2·0] vs 0·8 [0·4-1·5]; p=0·0033). Differences in FVC and DLCO persisted at last follow-up (median 34 months [IQR 19·8- 54·0] for FVC and median 34 months [IQR 22·5- 54·0] for DLCO). In the prevalent cohort, patients classified as IFN-high had a shorter median disease duration (2·2 years [IQR 0·7-8·2] vs 5·0 years [1·9-10·0]; p=0·035) compared to those classified as IFN-low, and worse 12-month lung outcomes independent of ba","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":" ","pages":""},"PeriodicalIF":15.0,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143781480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biologics first: evidence reshaping Still's disease treatment.","authors":"Yi-Ming Chen, Der-Yuan Chen","doi":"10.1016/S2665-9913(25)00033-5","DOIUrl":"https://doi.org/10.1016/S2665-9913(25)00033-5","url":null,"abstract":"","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":" ","pages":""},"PeriodicalIF":15.0,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143755254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First-line biological versus conventional synthetic disease-modifying antirheumatic drug therapy in adult-onset Still's disease: a multicentre, retrospective, propensity weighted cohort study.","authors":"Anna Kernder, Tim Filla, Rhea Friedrich, Norbert Blank, Diana Ernst, Jörg Henes, Gernot Keyßer, Philipp Klemm, Martin Krusche, Anna Meinecke, Jürgen Rech, Nils Schulz, Simon Michael Petzinna, Anne Pankow, Valentin S Schäfer, Alexander Pfeil, Sebastian Klapa, Eugen Feist, Stefan Vordenbäumen","doi":"10.1016/S2665-9913(25)00023-2","DOIUrl":"https://doi.org/10.1016/S2665-9913(25)00023-2","url":null,"abstract":"<p><strong>Background: </strong>Data on the efficacy of biological disease-modifying antirheumatic drug (DMARD) therapies such as anakinra, canakinumab, and tocilizumab as a primary therapeutic option in adult-onset Still's disease (AOSD) are scarce, and treatment recommendations rely mainly on data extrapolated from paediatric studies. The aim of this study was to compare the effectiveness of first-line biological DMARD therapy versus conventional synthetic DMARD therapy in AOSD.</p><p><strong>Methods: </strong>This multicentre, retrospective, propensity weighted cohort study was done at 16 secondary and tertiary rheumatology centres across Germany. Eligible patients were diagnosed with AOSD, met the Yamaguchi classification criteria, and had active disease without current treatment. All patients had documented follow-up assessments at weeks 12 and 72. The primary endpoint was sustained, event-free remission; a combined endpoint of sustained remission (C-reactive protein <10 mg/L and no arthritis, rash, or fever) and absence of complications during follow up in patients treated with first-line biological DMARDs (with or without glucocorticoids) or conventional synthetic DMARDs (methotrexate or glucocorticoids). Analysis was by propensity score weighted logistic regression, thereby balancing for the initial Pouchot score, ferritin concentration, and age and sex differences between groups. Analysis was done in the per protocol population. People with lived experience were not involved in the study design. The study is registered with the ISRCTN registry, ISRCTN86135778.</p><p><strong>Findings: </strong>Between Jan 1, 2007, and Sep 30, 2022, we screened 228 patients for inclusion. 142 patients were excluded, and 86 patients with AOSD who had an incident diagnosis or a flare without any maintenance treatment including glucocorticoids were enrolled and included in our analysis. 50 (58%) of 86 patients were female, 36 (42%) were male, and 84 (98%) were White. The mean age at inclusion was 39·4 years (SD 15·4). 44 (51%) of 86 had received a first-line biological DMARD and 42 (49%) received a first-line conventional synthetic DMARD. Biological DMARD therapy was associated with a greater likelihood of reaching the primary endpoint of sustained, event-free remission (OR 7·20, 95% CI 2·50-36·64; p=0·0007). At week 72, the rate of sustained, event-free remission was 50% (95% CI 34-65%; n=21) in the first-line biological DMARD group and 12% (3-23%; n=5) in the first-line conventional synthetic group. Glucocorticoid-related complications were more often described in the first-line conventional synthetic DMARD group (new-onset arterial hypertension [n=2] and glucocorticoid-related skin diseases [n=3]) versus none in the first-line biological DMARD group). Three (7%) of 42 patients in the conventional synthetic DMARD group died (two from macrophage activation syndrome, one unknown cause) versus none in the first-line biological DMARD group.</p><p><strong>Interp","PeriodicalId":48540,"journal":{"name":"Lancet Rheumatology","volume":" ","pages":""},"PeriodicalIF":15.0,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143755258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}